Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 5/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 4/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5112396 | 0.93 | F2 (0.39) | F2F10ELANEPRSS1METAP2 | |
| Trifluoroacetic Acid SCHEMBL5108973 | 0.92 | METAP2 (0.39) | F2F10ELANEMETAP2 | |
| Trifluoroacetic Acid SCHEMBL5108073 | 0.92 | F2 (0.37) | F2F10ELANEPRSS1METAP2 | |
| Trifluoroacetic Acid SCHEMBL5117325 | 0.92 | F2 (0.41) | F2F10ELANEMETAP2 | |
| Trifluoroacetic Acid SCHEMBL5116316 | 0.92 | METAP2 (0.38) | F2F10ELANEPRSS1PRSS2 | |
| Trifluoroacetic Acid SCHEMBL5115929 | 0.92 | KDM1A (0.41) | F2F10ELANEKDM1ACCR9 | |
| Trifluoroacetic Acid SCHEMBL5117912 | 0.92 | F2 (0.38) | F2F10ELANEPRSS1METAP2 | |
| Trifluoroacetic Acid SCHEMBL5117942 | 0.92 | METAP2 (0.40) | F2F10ELANEMETAP2KDM1A | |
| Trifluoroacetic Acid SCHEMBL5110436 | 0.91 | HSD17B2 (0.38) | F2F10ELANEKDM1ACCR9 | |
| Trifluoroacetic Acid SCHEMBL5110367 | 0.91 | ELANE (0.40) | F2F10ELANEKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6706021-B2 | ANTICOAGULANT FOR CATHETERS, DIALYSIS MACHINES, SYRINGES, TUBES, BLOOD LINES AND STENTS; TRYPSIN-LIKE SERINE PROTEASES SUCH AS THROMBIN; 3-BENZYLSULFONYLAMINO-6-METHYL-1-((2-GUANIDINOOXYETHYL) AMINOCARBONYLMETHYL)-2-PYRIDINONE | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6566379-B1 | As proteolytic enzyme inhibitors; thrombin inhibitors; for therapy of pancreatitis, thrombosis, ischemia, stroke, restenosis, emphysema or inflammation in a mammal | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | disclosed |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-01-17 | — | — | US | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | F2 26/4885F10 74/4885ELANE 261/4885 |
| US-20030225115-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | F2 28/4885F10 127/4885ELANE 291/4885 |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | F2 27/4885F10 115/4885ELANE 323/4885 |
| US-20020007070-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, PLAT | F2 26/4885F10 116/4885ELANE 304/4885 |
| US-20030087921-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, F2R | F2 28/4885F10 127/4885ELANE 291/4885 |
| US-20040106633-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | F2 27/4885F10 125/4885ELANE 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.